TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 30.79M USD | Liabilities, Current |
| Cash and equivalents | 176.23M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current · Available-for-sale Securities, Current |
| Customer receivables | 11.80M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $30.79M | $176.23M | (m) | $11.80M | (m) | (m) |
| 2026-03-31 | (m) | $29.65M | $185.47M | (m) | $8.82M | (m) | (m) |
| 2025-12-31 | (m) | $30.84M | $207.64M | (m) | $6.27M | (m) | (m) |
| 2025-09-30 | (m) | $21.03M | $190.06M | (m) | $3.48M | (m) | (m) |
| 2025-06-30 | (m) | $19.06M | $125.33M | (m) | $2.32M | (m) | (m) |
| 2025-03-31 | (m) | $12.15M | $131.72M | (m) | $3.31M | (m) | (m) |
| 2024-12-31 | (m) | $18.31M | $98.78M | (m) | $3.68M | $8.41M | (m) |
| 2024-09-30 | (m) | $15.18M | $28.23M | (m) | $4.01M | $7.93M | (m) |
| 2024-06-30 | (m) | $22.04M | $4.16M | (m) | $3.34M | $9.46M | (m) |
| 2024-03-31 | (m) | $20.48M | $7.05M | (m) | (m) | $12.35M | (m) |
| 2023-12-31 | (m) | $18.88M | $24.95M | (m) | (m) | $13.64M | (m) |
| 2023-09-30 | (m) | $17.73M | $6.91M | (m) | (m) | $13.32M | (m) |
| 2023-06-30 | (m) | $18.44M | $25.62M | (m) | (m) | $13.70M | (m) |
| 2023-03-31 | (m) | $13.07M | $71.97M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $18.18M | $120.23M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $13.34M | $139.98M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $15.91M | $145.48M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $15.35M | $140.44M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $21.72M | $178.66M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $12.03M | $182.97M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $8.08M | $165.72M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $6.03M | $164.21M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $9.82M | $77.07M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $4.38M | $55.66M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $4.68M | $55.02M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $2.66M | $30.66M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $5.13M | $11.25M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $2.37M | $10.02M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $2.05M | $12.15M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $2.01M | $16.45M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $2.65M | $25.03M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $2.35M | $14.67M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $2.51M | $16.68M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $2.36M | $19.25M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $2.13M | $25.50M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $1.84M | $29.31M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $1.83M | $34.35M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $1.78M | $19.94M | $2.48M | (m) | (m) | (m) |
| 2016-12-31 | (m) | $2.12M | $18.94M | $7.18M | (m) | (m) | (m) |
| 2016-09-30 | (m) | $2.62M | $15.64M | $11.09M | (m) | (m) | (m) |
| 2016-06-30 | (m) | $4.20M | $14.94M | $16.31M | (m) | (m) | (m) |
| 2016-03-31 | (m) | $3.91M | $8.43M | $16.58M | (m) | (m) | (m) |
| 2015-12-31 | (m) | $6.65M | $19.18M | $15.38M | (m) | (m) | (m) |
| 2015-09-30 | (m) | $5.10M | $33.01M | $22.04M | (m) | (m) | (m) |
| 2015-06-30 | (m) | $4.62M | $48.74M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $3.52M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $3.38M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $3.50M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $2.37M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $2.27M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $2.21M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $2.12M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $2.26M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $1.22M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $1.14M | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $836.80K | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $782.79K | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $284.25K | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $925.28K | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $340.28K | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |